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O B J E C T I V E S This study aimed to demonstrate that the presence of late gadolinium enhancement
(LGE) is a predictor of death and other adverse events in patients with suspected cardiac sarcoidosis.
B A C KG ROUND Cardiac sarcoidosis is the most important cause of patient mortality in systemic sarcoid-
osis, yielding a 5-year mortality rate between 25% and 66% despite immunosuppressive treatment. Other groups
have shown that LGE may hold promise in predicting future adverse events in this patient group.
METHOD S We included 155 consecutive patients with systemic sarcoidosis who underwent cardiac
magnetic resonance (CMR) for workup of suspected cardiac sarcoid involvement. The median follow-up time was
2.6 years. Primary endpoints were death, aborted sudden cardiac death, and appropriate implantable cardioverter-
deﬁbrillator (ICD) discharge. Secondary endpoints were ventricular tachycardia (VT) and nonsustained VT.
R E S U L T S LGE was present in 39 patients (25.5%). The presence of LGE yields a Cox hazard ratio (HR)
of 31.6 for death, aborted sudden cardiac death, or appropriate ICD discharge, and of 33.9 for any event.
This is superior to functional or clinical parameters such as left ventricular (LV) ejection fraction (EF), LV
end-diastolic volume, or presentation as heart failure, yielding HRs between 0.99 (per % increase LVEF)
and 1.004 (presentation as heart failure), and between 0.94 and 1.2 for potentially lethal or other adverse
events, respectively. Except for 1 patient dying from pulmonary infection, no patient without LGE died
or experienced any event during follow-up, even if the LV was enlarged and the LVEF severely impaired.
CONC L U S I O N S Among our population of sarcoid patients with nonspeciﬁc symptoms, the presence of
myocardial scar indicated by LGE was the best independent predictor of potentially lethal events, as well as other
adverse events, yielding aCoxHRof 31.6 andof 33.9, respectively. These data support the necessity for future large,
longitudinal follow-up studies to deﬁnitely establish LGE as an independent predictor of cardiac death in
sarcoidosis, as well as to evaluate the incremental prognostic value of additional parameters. (J Am Coll Cardiol
Img 2013;6:501–11) © 2013 by the American College of Cardiology Foundation
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VT ventricular tachycardia
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502ardiac involvement is the most important
cause of death in sarcoidosis patients,
yielding a 5-year mortality rate between
25% and 66% despite immunosuppressive
reatment (1–3). Because ventricular tachyarrhyth-
ias resulting from myocardial granulomas causing
lectric instability have been identified as the under-
ying mechanism of death (2,3), some patients may
enefit from implantable cardioverter-defibrillator
ICD) placement (4), yet risk stratification and clinical
anagement remain difficult (5).
Several groups recently determined that cardiac
agnetic resonance (CMR) using late gadolinium
nhancement (LGE), not only can improve the de-
ection of cardiac sarcoidosis in comparison to standard
linical evaluation with the use of consensus criteria (6,7),
but furthermore may hold promise in predict-
ing future adverse events, including cardiac
death, in this patient group.
Consequently, the primary objective of
this study was to establish the prognostic
value of a comprehensive CMR examina-
tion in risk stratification of patients with
suspected cardiac sarcoidosis. Specifically,
we sought to demonstrate that the pres-
ence of LGE visualized by CMR predicts
future lethal and other adverse events. In
addition, we aimed at identifying addi-
tional predictors for adverse events in this
patient group during long-term follow-up.
M E T H O D S
Patient population. One-hundred fifty-five
consecutive patients presenting at one of
the participating institutions between Jan-
uary 2002 and December 2011 for workup
of suspected cardiac sarcoidosis (all com-
ers) were prospectively enrolled in the long-term
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tember 28, 2012, accepted October 11, 2012.follow-up if they fulfilled the following criteria: 1) sys-
temic sarcoidosis diagnosed by biopsy and/or clinical
criteria; and 2) no history of coronary artery disease
or myocardial infarction; and 3) successfully under-
went CMR imaging (Table 1). Patients with val-
vular or congenital heart disease demonstrated by
CMR were not included. All patients gave in-
formed consent.
CMR protocol. Electrocardiogram (ECG)-gated
CMR imaging was performed in breath-hold using
a 1.5-T Magnetom Symphony, Magnetom Sonata,
Magnetom Espree, Magnetom Avanto, or Magne-
tom Aera magnetic resonance imaging scanner
(Siemens Healthcare, Erlangen, Germany) in line
with Society for Cardiovascular Magnetic Reso-
nance/European Cardiovascular Magnetic Reso-
nance recommendations (8). Both cine and LGE
short-axis CMR images were prescribed every 10
mm (slice thickness 6 mm) from base to apex.
In-plane resolution was typically 1.2  1.8 mm.
Cine CMR was performed using a steady-state
free-precession sequence. LGE images were ac-
quired on average 5 to 10 min after contrast
administration using segmented inversion recovery
fast gradient echo (9), constantly adjusting inver-
sion time (10). The contrast dose (gadodiamide or
gadopentetate dimeglumine) was 0.15 mmol/kg.
CMR analysis. Cine and contrast images were eval-
uated by 2 experienced observers as described else-
where (11,12). In brief, endocardial and epicardial
borders were outlined on the short-axis cine images.
Volumes and left ventricular (LV) ejection fraction
(EF) were derived by summation of epicardial and
endocardial contours. The LV mass was calculated
by subtracting endocardial from epicardial volume
at end-diastole and multiplying by 1.05 g/cm3 (13).
xtent of LGE was assessed using the Siemens
rgus analysis software package, and the results
ere expressed as percentage of myocardial mass.
here was good interobserver agreement when
nalyzing LVEF (kappa  0.92; p  0.001) and
GE extent (kappa  0.88; p  0.001).
Clinical follow-up. Clinical follow-up was performed
using a standardized questionnaire at least 3 months
after initial presentation. In case of a suspected
event, all necessary medical records were obtained
and reviewed by the authors acting as an endpoint
committee.
Variables, endpoints, and deﬁnitions. All variables
ere collected directly from patients and/or medical
ecords, except the CMR parameters, which wereB B R E V I A T I O N S
N D A C R O N YM S
CMR cardiac magnetic
resonance
ECG electrocardiogram
R hazard ratio
CD implantable
ardioverter-defibrillator
GE late gadolinium
nhancement
V left ventricle/ventricul
LVEDV left ventricular
end-diastolic volume
LVEF left ventricular eject
fraction
nsVT nonsustained ventri
tachycardia
RV right ventricle/ventricu
SCD sudden cardiac deathvaluated as described in the previous text. Vari-
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503ables include general characteristics and follow-up
results. Most variables are self-explanatory; all oth-
ers are defined in the following text.
There were 2 primary combined endpoints,
named endpoint 1 and endpoint 2. Endpoint 1 was
defined as either death, or aborted sudden cardiac
death (SCD), or appropriate ICD discharge. Thus,
Table 1. Baseline Patient Characteristics
All patients with follow-up 153 (98.7)
Time to follow-up, days 944 [454–1,553]
Female 62 (40.5)
Age, yrs 49.7 13
Diagnosis of sarcoidosis
Radiological 144 (94.1)
Clinical 69 (45.0)
Conﬁrmed by biopsy 127 (83.0)
Primary cardiac symptoms leading to CMR
Syncope 10 (6.5)
Palpitations 46 (30.1)
Angina 27 (17.6)
Clinical heart failure 6 (3.9)
ECG abnormality 43 (28.1)
Heart block 21 (7.3)
Wall motion abnormality 4 (2.6)
Reduced LVEF 12 (7.8)
Dyspnea 46 (30.1)
CMR imaging parameters
LVEF, % 63 [59–68]
LVEDV, ml 126 [105–155]
LVESV, ml 44 [33–61]
LV mass, g 122 [98–147]
LVEDD, mm 48 [44–52]
IVS, mm 11 [10–12]
LA dimension, cm 20 [18–24]
RA dimension, cm 19 [16–23]
PA, mm 25 [23–28]
LGE present* 39 (25.5)
LGE, % of LV mass 4.4 [2.9–8.8]
Events during follow-up
Death 4 (2.6)
Aborted SCD 4 (2.6)
ICD shocks 7 (4.6)
VT 6 (3.9)
nsVT 14 (9.1)
Values are n (%), median [IQR], or mean SD. *Values are for all patients with
sarcoidosis (N  155).
CMR  cardiac magnetic resonance; ECG  electrocardiogram;
EDV  end-diastolic volume; ESV  end-systolic volume; heart block 
sinoatrial or atrioventricular or bundle branch block; ICD  implantable
cardioverter-deﬁbrillator; IQR  interquartile range; IVS  interventricular
septum; LA  left atrium; LGE  late gadolinium enhancement; LV  left
ventricular; LVEDD  left ventricular end-diastolic diameter; LVEDV  left
ventricular end-diastolic volume; LVEF  left ventricular ejection fraction;
LVESV  left ventricular end-systolic volume; nsVT  nonsustained ventric-
ular tachycardia; PA  pulmonary artery; RA  right atrium; SCD  sudden
cardiac death; VT  ventricular tachycardia.endpoint 1 could only be reached by experiencing a ahard, “potentially lethal” event such as death or
aborted death. Endpoint 2 was defined as either
endpoint 1, or ventricular tachycardia (VT) or
nonsustained ventricular tachycardia (nsVT). Con-
sequently, endpoint 2 could be reached by experi-
encing either a potentially lethal or a soft event such
as VT or nsVT. The explicit meaning of the events
is described in the following paragraphs:
Death: death from any cause.
Aborted SCD: resuscitation after cardiac arrest
defined as performance of the physical act of
cardioversion and/or cardiopulmonary resus-
citation in a patient who remains alive 28 days
later.
Appropriate ICD shocks: defibrillator discharges
considered appropriate included automatic
defibrillation shocks triggered by VT or ven-
tricular fibrillation and documented by stored
intracardiac electrocardiographic data.
VT: 3 or more ventricular beats with a frequency
of more than 120 beats/min, lasting longer
than 30 s.
nsVT: 3 or more ventricular beats with a fre-
quency of more than 120 beats/min, lasting
up to 30 s.
Statistical analysis. Absolute numbers and percentages
were computed to describe the patient population. Me-
dians (with quartiles) or means (with standard deviation)
were computed as appropriate. Patients with and without
LGE (Table 2), with endpoint and without any end-
point events (Tables 3 and 4) were compared by
hi-square test or Fisher exact test as appropriate
categorical values) and Wilcoxon signed rank test
continuous values). Additionally, univariate odds ra-
ios with 95% confidence intervals were calculated for
ichotomous parameters. Kaplan-Meier curves were
alculated for visualizing the cumulative survival free
f events of patients with and without LGE. Log-
ank tests were performed to compare survival curves.
ultivariable Cox proportional hazard models were
sed for analyzing independent associations with de-
ned endpoints. Values of p  0.05 were considered
ignificant. All p values are results of 2-tailed tests. All
tatistical analyses were performed using the SAS
tatistical package, version 9.2 (SAS Institute, Cary,
orth Carolina).
R E S U L T S
Patient characteristics. One-hundred fifty-three of
ll 155 patients were available for clinical follow-
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504up, yielding a follow-up rate of 98.7%. The
remaining 2 patients were lost due to no contact.
The following paragraphs describe the character-
istics of the 153 patients who underwent clinical
follow-up.
At inclusion, patients were 50  13 years of age.
All were initially diagnosed with systemic sarcoid-
osis by clinical and/or radiological criteria. The
diagnosis of systemic sarcoidosis was confirmed by
noncardiac biopsy in 83%. Palpitations and dyspnea
were the primary reason to suspect cardiac sarcoid-
osis (n  46, respectively), followed by ECG abnor-
malities (n 43) and various combinations of angina,
Table 2. Characteristics of Patients With and Without LGE
LGE Present
(n  39)
Age, yrs 51.0 14.7
Female 10 (25.6)
Diagnosis of sarcoidosis
Radiological 36 (92.3)
Clinical 13(33.3)
Conﬁrmed by biopsy 34 (87.2)
Cardiac symptoms leading to CMR
Syncope 5 (12.8)
Palpitations 10 (25.6)
Angina 7 (17.9)
Clinical heart failure 4 (10.2)
ECG abnormality 13 (33.3)
Heart block 7 (17.9)
Wall motion abnormality 2 (5.1)
Reduced LVEF 7 (17.9)
Dyspnea 16 (41.0)
CMR imaging parameters
LVEF, % 55.0 [46.0–66.0]
LVEDV, ml 140.0 [96.0–196.0]
LVESV, ml 58.0 [35.0–90.0]
LV mass, g 140.5 [112.0–164.0]
LVEDD, mm 50.0 [45.0–55.0]
IVS, mm 11.0 [10.0–13.0]
LA dimension, cm2 21.5 [19.0–25.0]
RA dimension, cm2 20.5 [18.0–26.0]
PA, mm 26.0 [25.0–29.0]
LGE present, % 39 (100.0)
LGE, % of LV mass 4.4 [2.9–8.8]
Events during follow-up
Death 3 (7.7)
Aborted SCD 4 (10.3)
ICD shocks 7 (17.9)
VT 6 (15.3)
nsVT 14 (35.8)
Values are mean  SD, n (%), or median [IQR].
CI  conﬁdence interval; OR  odds ratio; other abbreviations as in Table 1.heart failure, and other symptoms (Table 1).Systemic sarcoidosis was treated according to
current guidelines during the entire follow-up. In
addition, all patients with heart failure received
state-of-the-art heart failure medication. If indi-
cated clinically, ICD implantation was offered,
which was accepted by 13 patients.
CMR ﬁndings. The mean LVEF was 63%, and the
mean LV end-diastolic volume (LVEDV) was 126 ml
(Table 1). LGE was present in 39 of 153 patients,
most commonly occurring in a non-coronary artery
disease pattern at the right ventricle (RV) side of
the interventricular septum, followed by a patchy
intramural or transmural distribution in the entire
No LGE
(n  114) p Value OR (95% CI)
49.2 12.4 0.65
52 (45.6) 0.05 0.42 (0.19–0.95)
108 (94.7) 0.72 1.33 (0.27–6.57)
56 (49.1) 0.10 0.53 (0.25–1.13)
93 (81.5) 0.42 1.54 (0.54–4.39)
5 (4.3) 0.06 3.33 (0.91–12.22)
36 (31.5) 0.56 0.78 (0.34–1.78)
20 (17.5) 0.89 1.07 (0.41–2.78)
2 (1.7) 0.05 6.65 (1.17–37.88)
30 (26.3) 0.33 1.47 (0.67–3.24)
14 (12.3) 0.52 0.79 (0.34–1.71)
2 (1.7) 0.24 3.14 (0.43–23.09)
5 (4.3) 0.01 4.97 (1.47–16.74)
30 (26.3) 0.06 2.06 (0.96–4.44)
65.0 [60.5–70.0] 0.0001
125.0 [107.0–146.0] 0.22
43.0 [33.0–54.5] 0.01
117.0 [96.0–140.0] 0.01
48.0 [44.0–51.0] 0.06
11.0 [10.0–12.0] 0.05
20.0 [18.0–23.0] 0.05
19.0 [16.0–22.0] 0.05
25.0 [23.0–27.0] 0.01
0 (0.0)
0.0
1 (0.8) 0.05 9.42 (0.95–93.37)
0 (0.0) 0.001
0 (0.0) 0.0001
0 (0.0) 0.0001
0 (0.0) 0.0001LV. In addition, LGE was also observed in the RV
t
s
S
p
a
i
r
(
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 4 , 2 0 1 3
A P R I L 2 0 1 3 : 5 0 1 – 1 1
Greulich et al.
Risk Stratification in Patients With Sarcoidosis
505free wall or the RV outflow tract. Most patients
with LGE underwent x-ray coronary angiography,
and none had evidence of obstructive coronary
disease.
Dividing our patient population into groups with
and without LGE reveals that patients with LGE
had larger ventricles, poorer LVEF, and were more
likely to have clinical symptoms of heart failure
(Table 2). Typical CMR results are displayed in
Table 3. Univariate Analysis Endpoint 1—Death or Aborted SCD
Endpoint 1
(n  12)
Age, yrs 54.8 16.5
Female 4 (33.3)
Diagnosis of sarcoidosis
Radiological 10 (83.3)
Clinical 1 (8.3)
Conﬁrmed by biopsy 10 (83.3)
Cardiac symptoms leading to CMR
Syncope 3 (25.0)
Palpitations 1 (8.3)
Angina 3 (25.0)
Clinical heart failure 1 (8.3)
ECG abnormality 4 (33.3)
Heart block 4 (33.3)
Wall motion abnormality 1 (8.3)
Reduced LVEF 2 (16.7)
Dyspnea 8 (66.7)
CMR imaging parameters
LVEF, % 52.0 [48.0–58.0]
LVEDV, ml 112.5 [98.0–150.0]
LVESV, ml 58.5 [40.5–70.5]
LV mass, g 128.5 [110.0–167.5]
LVEDD, mm 48.0 [42.0–50.5]
IVS, mm 13.5 [10.5–15.5]
LA dimension, cm2 20.5 [19.5–23.5]
RA dimension, cm2 25.0 [21.0–28.5]
PA, mm 28.0 [25.5–30.0]
LGE present 91.7 [11.0–12.0]
LGE, % of LV mass 7.4 [2.9–14.7]
Events during follow-up*
Death 4 (33.3)
Aborted SCD 4 (33.3)
ICD shocks 7 (58.3)
Medication ever during follow-up
Steroids 8 (66.6)
Methotrexate 0 (0.0)
Azathioprine 0 (0.0)
Inﬂiximab 0 (0.0)
Others 0 (0.0)
Values are mean  SD, n (%), or median [IQR]. *3 patients had aborted SCD as
SCD.
Abbreviations as in Tables 1 and 2.Figure 1. eFollow-up results. During follow-up, 4 of 153 pa-
ients died, 4 patients experienced SCD but were
uccessfully resuscitated, and 7 patients survived
CD due to appropriate ICD discharge. Because 3
atients experienced aborted SCD, as well as an
ppropriate ICD discharge occurring after ICD
mplantation due to aborted SCD, 12 patients
eached endpoint 1 as described in the previous text
Table 3). Almost all of these potentially lethal
Adequate ICD Discharge
No Endpoint
(n  141) p Value OR (95% CI)
49.1 12.7 0.23
56 (39.7) 0.66 0.76 (0.22–2.64)
133 (94.3) 0.10 0.26 (0.05–1.44)
67 (47.5) 0.01 0.10 (0.01–0.80)
116 (82.2) 0.97 1.03 (0.21–5.03)
7 (4.9) 0.01 6.33 (1.40–28.72)
45 (31.9) 0.08 0.19 (0.02–1.53)
24 (17.0) 0.49 1.61 (0.41–6.40)
5 (3.5) 0.42 2.45 (0.26–22.90)
39 (27.6) 0.69 1.29 (0.37–4.55)
17 (12.0) 0.36 2.71 (0.26–21.90)
3 (2.1) 0.20 4.15 (0.40–43.32)
10 (7.1) 0.24 2.60 (0.50–13.52)
38 (26.9) 0.01 5.37 (1.53–18.86)
64.0 [60.0–69.0] 0.01
126.0 [107.0–155.0] 0.39
44.0 [33.0–59.0] 0.22
122.0 [97.0–147.0] 0.35
48.0 [44.0–52.0] 0.65
11.0 [10.0–12.0] 0.05
20.0 [18.0–24.0] 0.91
19.0 [16.0–22.0] 0.01
25.0 [23.0–28.0] 0.05
19.9 [28.0–141.0] 0.0001 44.39 (5.50–358.4)
4.4 [2.9–7.4] 0.43
—
—
—
102 (72.3) 0.08
7 (4.9) 0.52
11 (7.8) 0.41
1 (0.7) 0.81
18 (12.7) 0.28
as an adequate ICD discharge occurring after ICD implantation due to abortedor
wellvents (n  11) occurred for cardiac reasons.
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506In addition, 20 VTs or nsVTs were documented
on Holter ECG during follow-up (Table 4). The
average Holter monitoring time during follow-up
was 2.6 days per patient. Note that only 1 patient
without LGE died (Table 2). This patient died
from rapid pulmonary infection, which she devel-
oped during immunosuppressive treatment for sys-
Table 4. Univariate Analysis Endpoint 2—Death or Aborted SCD
Endpoint 2
(n  20)
Age, yrs 54.6 15.5
Female 7 (35.0)
Diagnosis of sarcoidosis
Radiological 18 (90.0)
Clinical 4 (20.0)
Conﬁrmed by biopsy 18 (90.0)
Cardiac symptoms leading to CMR
Syncope 4 (20.0)
Palpitations 4 (20.0)
Angina 3 (15.0)
Clinical heart failure 3 (15.0)
ECG abnormality 6 (30.0)
Heart block 6 (30.0)
Wall motion abnormality 1 (5.0)
Reduced LVEF 7 (35.0)
Dyspnea 10 (50.0)
CMR imaging parameters
LVEF, % 48.0 [41.5–54.5]
LVEDV, ml 150.0 [101.5–204.5]
LVESV, ml 70.5 [56.0–106.5]
LV mass, g 139.0 [108.0–165.0]
LVEDD, mm 50.5 [47.5–59.0]
IVS, mm 11.0 [9.5–14.0]
LA dimension, cm2 23.0 [20.0–28.0]
RA dimension, cm2 25.0 [19.0–27.0]
PA, mm 28.0 [26.0–30.0]
LGE present 95.0 [19.0–20.0]
LGE, % of LV mass 5.9 (2.9–14.7)
Events during follow-up*
Death 4 (20.0)
Aborted SCD 4 (20.0)
ICD shocks 7 (35.0)
VT 6 (30.0)
nsVT 14 (70.0)
Medication ever during follow-up
Steroids 16 (80.0)
Methotrexate 1 (5.0)
Azathioprine 1 (5.0)
Inﬂiximab 0 (0.0)
Others 0 (0.0)
Values are mean  SD, n (%), or median [IQR]. *8 patients had 2 or more even
Abbreviations as in Tables 1 and 2.temic sarcoidosis. Furthermore, no patient with inormal CMR upon initial presentation (defined as
LVEF 60% and LVEDV 180 ml and no LGE)
ied or experienced any other event during
ollow-up (n  92).
Predictors of events. For evaluation of predictors for
dverse events, we looked at: 1) all patients who
eached endpoint 1 (potentially lethal events only,
Adequate ICD Discharge or VT or nsVT
No Endpoint
(n  133) p Value OR (95% CI)
48.8 12.5 0.11
53 (39.8) 0.68 0.81 (0.30–2.17)
125 (93.9) 0.41 0.50 (0.10–2.62)
64 (48.1) 0.05 0.27 (0.09–0.85)
108 (81.2) 0.37 2.00 (0.43–9.20)
6 (4.5) 0.01 5.25 (1.34–20.62)
42 (31.5) 0.28 0.54 (0.17–1.70)
24 (18.0) 0.73 0.79 (0.22–2.93)
3 (2.2) 0.01 7.59 (1.42–40.65)
37 (27.8) 0.86 1.10 (0.39–3.08)
15 (11.2) 0.26 0.74 (0.11–1.80)
3 (2.2) 0.48 2.26 (0.22–22.89)
5 (3.7) 0.0001 13.68 (3.80–49.28)
36 (27.0) 0.05 2.67 (1.02–6.94)
65.0 [61.0–69.0] 0.0001
124.0 [105.0–148.0] 0.13
43.0 [33.0–55.0] 0.001
121.0 [96.5–145.0] 0.09
48.0 [44.0–51.0] 0.05
11.0 [10.0–12.0] 0.37
20.0 [18.0–23.0] 0.06
18.5 [16.0–22.0] 0.001
25.0 [23.0–27.0] 0.001
15.0 [20.0–133.0] 0.0001 107.4 (13.60–847.6)
4.4 (2.9–5.9) 0.36
—
—
—
—
—
94 (70.7) 0.05
6 (4.5) 0.76
10 (7.5) 0.85
1 (0.8) 0.73
18 (13.5) 0.12
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507propriate ICD discharge) (Table 3); and 2) all
patients who experienced any event (potentially
lethal or other event, including VT and nsVT)
(Table 4).
There is no significant correlation between events
and clinical presentation except syncope, which may
be a surrogate parameter for undetected arrhyth-
mias, and symptoms of heart failure, which is a
surrogate parameter of impaired LVEF.
In addition, functional parameters such as
LVEF, LVEDV, as well as the presence of LGE
reached statistical significance. In fact, the presence
of LGE yields an odds ratio for a potentially lethal
event of 44.4 (endpoint 1), and of 107.4 for any
event (endpoint 2, including VT and nsVT). Typ-
ical examples are displayed in Figure 2.
Kaplan-Meier survival curves for endpoint 1 and
endpoint 2 comparing patients with LGE to pa-
tients without LGE are displayed in Figures 3A and
3B. Note that only 1 patient without LGE died
during follow-up (pulmonary infection as described
in the previous text).
Multivariable Cox regression analysis including
the presence of LGE, the initial LVEF, the initial
Figure 1. Typical CMR Results in the Setting of Cardiac Sarcoido
Cardiac magnetic resonance (CMR) of a 48-year-old woman present
tricular block. Cine images reveal a normal left ventricle (LV) with p
enhancement (LGE) is present in multiple locations (white arrows)
cardiac sarcoidosis in the LV and right ventricle. This patient receive
tained ventricular tachycardia, which discharged appropriately seve
blockers. LAX  long axis; LVEDV  left ventricular end-diastolic voLVEDV, and the initial presentation as heart fail-ure also revealed LGE as the best independent
predictor of potentially lethal events (p  0.0014,
azard ratio [HR]: 31.6 for endpoint 1). In this
odel, neither initial LVEDV (p  0.06, HR:
.001 per ml increase in LVEDV), nor initial
VEF (p  0.34, HR: 0.99 per % increase in
VEF), nor clinical presentation as heart failure
p 0.97, HR: 1.04) reached significance. Looking
t patients experiencing any event (endpoint 2),
GE was the best independent predictor (p  0.001,
R: 33.9). However, in this model, initial LVEF
p  0.04, HR: 0.94 per % increase in LVEF) and
VEDV (p  0.046, HR: 1.004 per ml increase in
VEDV), but not presentation as heart failure (p
.69, HR: 1.2), also reached significance.
D I S C U S S I O N
This study is unique in that we could demonstrate
that the presence of LGE is the best independent
predictor of death and other adverse events in
patients presenting for workup of suspected cardiac
sarcoidosis in an international multicenter setting.
Our data not only confirm earlier single-center
with shortness of breath and new onset of third-degree atrioven-
rved left ventricular ejection fraction (LVEF). Late gadolinium
ing up to 14.7% of LV mass. Endomyocardial biopsy conﬁrmed
n implantable cardioverter-deﬁbrillator due to reoccurring sus-
imes during follow-up despite amiodarone and high-dose beta-
e; LVESV  left ventricular end-systolic volume.sis
ing
rese
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d a
ral tfindings in smaller groups (6,7), suggesting a po-
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508tential use of LGE in the setting of cardiac sarcoid-
osis, but clearly indicate a clinical role for LGE for
noninvasive risk stratification of sarcoid patients,
yielding a Cox HR of 31.6 for endpoint 1 and of
33.9 for endpoint 2. This is superior to functional or
clinical parameters such as LVEF, LVEDV, or
presentation as heart failure, yielding HRs between
0.99 and 1.004, and between 0.94 and 1.2 for
endpoints 1 and 2, respectively. Importantly, except
for the 1 patient dying from pulmonary infection
reported in the previous text, no patient without
LGE died or experienced any event during follow-
up, even if the LV was enlarged and the LVEF
severely impaired (LVEDV 180 ml and LVEF
35% and no LGE; n  3) (Fig. 4).
Patient characteristics. Cardiac sarcoidosis was sus-
ected due to palpitations and dyspnea (n  46,
espectively) in most patients, followed by ECG
bnormalities (n  43), and various combinations
f angina, heart failure, and other symptoms (Table 1),
hich is in line with previous reports (6,7). Also,
he average patient age in our population is similar
o previous reports of cardiac sarcoidosis (6,7,14) or
yocarditis (15), but lower than in other nonisch-
mic cardiomyopathies (16). However, in compar-
son to previous studies, our patients were less
ymptomatic on average, which is nicely reflected by
he fact that in the current population, the median
Figure 2. Typical Example of Patients With LGE With an Event V
The upper panel demonstrates CMR ﬁndings of a 46-year-old man
normal LVEF with diffuse LGE located mainly in the interventricular
arrows). During follow-up, he received an implantable cardioverter-
resuscitation, and was shocked appropriately several times. The bot
sy-proven systemic sarcoidosis. This patient also had an almost-nor
up. Abbreviations as in Figure 1.VEF at presentation was 63%. sCMR ﬁndings. Despite a median LVEF of 63%,
ome patients presented with dilated ventricles
nd/or impaired function. LGE was present in 39
f 153 patients, and was usually located at the RV
ide of the interventricular septum, followed by a
atchy intramural or transmural distribution in the
ntire LV, in line with other reports (7).
Furthermore, our data demonstrate that patients
ith scar indicated by LGE have larger ventricles and
oorer LVEF compared with those without scar
Table 2). This finding matches the results from other
nflammatory (15) or nonischemic cardiomyopathy
16) populations, but is different from the results
eported by Patel et al. (7) in cardiac sarcoid patients.
owever, this discrepancy is most likely explained by
he systematic exclusion of patients with depressed LV
unction in the study of Patel et al (7).
Follow-up results and predictors of events. In our
population of patients with nonspecific symptoms,
12 patients died or had aborted sudden cardiac
death or appropriate ICD discharge, and reached
endpoint 1, as described in the previous text, during
a median follow-up time of 2.6 years (Table 3),
yielding a hard event rate of 3% per year. The
majority of these events (n  11) occurred for
ardiac reasons. Thus, the cardiac mortality of our
arcoid patients is lower than that reported previ-
usly (1–3), most probably due to a lower disease
us Patients Without LGE Without Any Events
biopsy-proven systemic sarcoidosis. This patient has an almost
tum and the inferior and lateral wall (26.4% of LV mass, white
brillator (ICD) after sudden cardiac death (SCD) and successful
row demonstrates CMR images of a 41-year-old man with biop-
LVEF but no LGE and did not experience an event during follow-ers
with
sep
deﬁ
tom
maleverity upon inclusion. However, the annual mor-
) du
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509tality is about 60% of the nonischemic cardiomy-
opathy group of the SCD-HeFT (Sudden Cardiac
Death in Heart Failure Trial) (3% vs. 5%) (17),
although LV function was much better in our
patients (median 63%), underscoring the impor-
tance of risk stratification and optimal clinical
management in cardiac sarcoidosis.
In clinical routine, however, risk stratification
based on clinical and functional parameters remains
difficult despite the value of LVEF, LVEDV, and
clinical symptoms (2,18,19). For example, in the
current study, 4 patients without any clinical signs
of heart failure experienced SCD (Table 3), and 15
additional patients without heart failure had docu-
mented VT or nsVT (Table 4). In addition, several
patients suffered an adverse event despite only
mildly impaired LV function (endpoint 1: n  11,
LVEF 45%; endpoint 2: n  14, LVEF 45%)
or a normal sized LV (endpoint 1: n 10, LVEDV
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Figure 3. Kaplan-Meier Survival Curves
Kaplan-Meier survival curves with regard to endpoint 1 (A, includin
point 2 (B, including death, aborted SCD, appropriate ICD discharge
The number of patients at risk is shown at the bottom of the ﬁgur
enced an event (death due to pulmonary infection, see text for details180 ml; endpoint 2: n  12, LVEDV 180 ml).Other factors, such as ECG abnormalities, sug-
gested to be of prognostic value in cardiac sarcoid by
previous studies (18,19) could not be confirmed,
despite a trend toward a poorer outcome in patients
with palpitations or syncope in their medical history
(Table 3).
Our findings fit to the fact that LGE is also a
good predictor of adverse events in other nonisch-
emic heart diseases, such as myocarditis (15) or
hypertrophic cardiomyopathy (16). These results
may help to explain why only 1 patient without
LGE suffered any event (1 of 114) (Table 2), who
died for noncardiac reasons from pulmonary infec-
tion as described in the previous text. Note that not
a single patient without LGE had VT or nsVT
during follow-up. This concept is highlighted by
Figures 2 and 4.
Even with these encouraging data, however, it is
important to keep in mind that there is not a 1-to-1
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p-log-rank < 0.0001
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R
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LGE
ath, aborted SCD, and appropriate ICD discharge only), and end-
well as ventricular tachycardia [VT] and nonsustained VT [nsVT]).
te that in the group without any LGE, only a single patient experi-
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510cardiac death. Thus, to further improve possible
CMR risk stratification, we also thought about a
possible incremental value of additional CMR-
related parameters, such as the pattern of LGE
(12), or scar volume and surface area (16). However,
we were not able to discriminate their individual
predictive potential due to the limited number of
cases and events available in the present study.
Clinical implications. Although our data demonstrate
n association between LGE and death as well as
ther adverse events in sarcoid patients with non-
pecific symptoms, additional multicenter data from
andomized studies and the EuroCMR Registry
20,21) are required to definitively establish LGE as
ausally related to death risk. Additional data are
lso needed to determine the value of an additional
lectrophysiology study in CMR-positive patients
s suggested by the pilot data of Mehta et al. (14).
owever, with regard to our data and the results
rom other groups, some speculations can be made
hat may influence current clinical management: 1)
arcoid patients with normal CMR (LVEF 60%
nd LVEDV 180 ml and no LGE) seem to have
good prognosis, independent of clinical symp-
oms, which may give suffering patients and worry-
ng physicians some peace of mind; 2) sarcoid
atients without LGE did not experience SCD or
T in our study, even if the LV was dilated and the
VEF severely impaired. Consequently, if LGE
Figure 4. Typical Patient Examples Illustrating LGE as a Better P
The upper panel displays typical CMR results of a 31-year-old wom
multiple patchy foci of LGE in the left and right ventricles (white a
tated. Unfortunately, her systolic function worsened over time, and
CMR images of another female patient with even more severely im
with patient 28 (upper panel), she experienced no events during fond not LV function or size is closer to the substrateor SCD, it may be prudent to treat all sarcoid
atients demonstrating LGE with beta-blockers,
ndependent of LV function and size, to prevent
otentially lethal arrhythmias. This speculation sat-
sfactorily fits to the results of Grün et al. (15)
eporting the same relation between LGE and
rrhythmic events in myocarditis, as well as the
esults of Kindermann et al. (22) describing the lack
f beta-blocker therapy as a predictor for poor
linical outcome in inflammatory heart disease; and
) we also found impaired LVEF and enlarged
VEDV as predictors for adverse events. Thus, one
hould carefully optimize heart failure therapy in all
arcoid patients presenting with even the mildest
igns of heart failure.
Study limitations. The relatively low number of
events is an important limitation of this study. This
prevented us from evaluating the predictive poten-
tial of other parameters such as the pattern of LGE,
scar transmurality, scar surface area, and so on. In
addition, it may be possible that CMR reports
influenced treatment decisions with regard to ICD
implantation, which may result in more endpoints
such as ICD shocks to be detected in patients with
abnormal CMR results.
C O N C L U S I O N S
Among our population of sarcoid patients with
ictor of Events Than Other Parameters (Such as LVEF)
ith biopsy-proven sarcoidosis. Initially, her LVEF was 41% with
s). She had SCD during follow-up and was successfully resusci-
had to undergo heart transplant later. The bottom panel shows
ed LVEF (33%) but no LGE. Despite the worse LVEF compared
-up. Abbreviations as in Figures 1 and 2.red
an w
rrow
she
pairnonspecific symptoms, the presence of myocardial
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511scar indicated by LGE is the best independent
predictor of potentially lethal, as well as other
adverse events, yielding a Cox HR of 31.6 and of
33.9, respectively. These data support the necessity
for future large longitudinal follow-up studies to
definitely establish LGE as an independent predic-al. Detection of myocardial damage in
1
1
1
1
1
1
proven viral myocarevaluate the incremental prognostic value of addi-
tional parameters.
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